TABLE 1.

Repurposed Drugs and Device

Drug	Manufacturer	Original indication	Date of approval, licensure or clearance	Repurposed indication(s)
Neupogen (filgrastim)	Amgen Inc.	Neutropenia	1991	Licensed for H-ARS in 2015
Neulasta (pegfilgrastim)	Amgen Inc.	Neutropenia	2002	Licensed for H-ARS in 2015
Xigris (Drotrecogin alfa; activated protein C)	Eli Lilly and Co.	Sepsis	2002; withdrawn 2011	BARDA-funded for H-ARS
Silverlon (calcium alginate dressing)	Argentum Medical	First- and second-degree burns	Clearance 1998	BARDA-funded for Cutaneous radiation injuries
Mozobil (plerixafor)	AnorMED	Mobilize CD34+ mesenchymal stem cells	2008	NIAID-funded for H-ARS, tissue repair
Surfaxin (lucinactant)	Discovery Labs	Neonatal respiratory distress	2012	NIAID-funded for radiation-induced lung injury
Prinivil® (lisinopril)	Merck & Co. Inc.	Hypertension	1987	NIAID-funded for radiation-induced lung injury
Vasotec® (enalapril)	Merck & Co. Inc.	Hypertension	1981	NIAID-funded for radiation-induced lung injury
Capoten® (captopril)	Bristol-Myers Squibb	Hypertension	1981	NIAID-funded for radiation-induced kidney and lung injury
Ciprofloxacin (fluoroquinolone)	Bayer Corp.	Antibiotic	1987	NIAID-funded for radiation combined injury